Literature DB >> 8010943

Differences in methotrexate and 7-hydroxymethotrexate inhibition of folate-dependent enzymes of purine nucleotide biosynthesis.

J E Baggott1, S L Morgan, W H Vaughn.   

Abstract

7-Hydroxymethotrexate (7-OH-MTX) is the major and, frequently the only, pteridine metabolite found in bone-marrow aspirates of patients chronically treated with low-dose oral methotrexate (MTX) [Sonneveld, Schultz, Nooter and Hahlen (1986) Cancer Chemother. Pharmacol. 18, 111-116]. The Ki values for MTX and 7-OH-MTX for avian liver 5-amino-imidazole-4-carboxamide ribonucleotide transformylase differ by 4.5-fold in favour of 7-OH-MTX as the better inhibitor, while Ki values for avian liver glycinamide ribonucleotide transformylase differ by 1.9-fold favouring MTX as the better inhibitor. Thus 7-OH-MTX possesses a different enzyme-inhibiting repertoire from its parent drug and this information may be useful in explaining the mechanism of action of low-dose MTX therapies used to treat autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8010943      PMCID: PMC1138213          DOI: 10.1042/bj3000627

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  13 in total

1.  Formation of 7-hydroxymethotrexate polyglutamyl derivatives and their cytotoxicity in human chronic myelogenous leukemia cells, in vitro.

Authors:  G Fabre; I D Goldman
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

2.  Pharmacokinetic interactions with methotrexate: is 7-hydroxy-methotrexate the culprit?

Authors:  L Slørdal; G Sager; J Aarbakke
Journal:  Lancet       Date:  1988-03-12       Impact factor: 79.321

3.  Polyglutamyl folate coenzymes and inhibitors of chicken liver glycinamide ribotide transformylase.

Authors:  V T Chan; J E Baggott
Journal:  Biochim Biophys Acta       Date:  1982-03-18

4.  Synthesis and properties of 7-hydroxymethotrexate polyglutamyl derivatives in Ehrlich ascites tumor cells in vitro.

Authors:  G Fabre; I Fabre; L H Matherly; J P Cano; I D Goldman
Journal:  J Biol Chem       Date:  1984-04-25       Impact factor: 5.157

5.  A simple preparation of the methotrexate metabolites 7-hydroxymethotrexate and 4-deoxy-4-amino-N10-methylpteroic acid.

Authors:  D A Cairnes; W E Evans
Journal:  Ther Drug Monit       Date:  1983       Impact factor: 3.681

6.  Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy.

Authors:  R Erttmann; S Bielack; G Landbeck
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  L(-)-10-Formyltetrahydrofolate is the cofactor for glycinamide ribonucleotide transformylase from chicken liver.

Authors:  G K Smith; P A Benkovic; S J Benkovic
Journal:  Biochemistry       Date:  1981-07-07       Impact factor: 3.162

8.  Comparative study on the pharmacokinetics of 7-hydroxy-methotrexate after administration of methotrexate in the dose range of 0.5-33.6 g/m2 to children with acute lymphoblastic leukemia.

Authors:  J D Borsi; E Sagen; I Romslo; P J Moe
Journal:  Med Pediatr Oncol       Date:  1990

9.  7-Hydroxymethotrexate cytotoxicity and selectivity in a human Burkitt's lymphoma cell line versus human granulocytic progenitor cells: rescue by folinic acid and nucleosides.

Authors:  I Fabre; G Fabre; J P Cano
Journal:  Eur J Cancer Clin Oncol       Date:  1986-10

10.  Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide.

Authors:  J E Baggott; W H Vaughn; B B Hudson
Journal:  Biochem J       Date:  1986-05-15       Impact factor: 3.857

View more
  6 in total

1.  Cofactor role for 10-formyldihydrofolic acid.

Authors:  J E Baggott; G L Johanning; K E Branham; C W Prince; S L Morgan; I Eto; W H Vaughn
Journal:  Biochem J       Date:  1995-06-15       Impact factor: 3.857

2.  Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation.

Authors:  Joseph E Baggott; Sarah L Morgan
Journal:  Arthritis Rheum       Date:  2009-08

3.  High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model.

Authors:  E Smeland; O M Fuskevåg; K Nymann; J S Svendesn; R Olsen; S Lindal; R M Bremnes; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 4.  Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease.

Authors:  Emilio G Quetglas; Zlatan Mujagic; Simone Wigge; Daniel Keszthelyi; Sebastian Wachten; Ad Masclee; Walter Reinisch
Journal:  World J Gastroenterol       Date:  2015-11-28       Impact factor: 5.742

Review 5.  Oral medications for central serous chorioretinopathy: a literature review.

Authors:  William Fusi-Rubiano; Habiba Saedon; Vijay Patel; Yit C Yang
Journal:  Eye (Lond)       Date:  2019-09-16       Impact factor: 3.775

Review 6.  Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers.

Authors:  Philip M Brown; Arthur G Pratt; John D Isaacs
Journal:  Nat Rev Rheumatol       Date:  2016-10-27       Impact factor: 20.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.